Biotechnology

GlycoMimetics

$3.92
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.05 (+1.30%) Today
+$0.03 (+0.77%) As of 11:49 AM UTC after-hours

Why Robinhood?

You can buy or sell GlycoMimetics and other stocks, options, and ETFs commission-free!

About GLYC

GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease-related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD. The listed name for GLYC is GlycoMimetics, Inc. Common Stock.

CEO
Rachel K. King
Employees
57
Headquarters
Rockville, Maryland
Founded
2003
Market Cap
184.60M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
642.80K
High Today
$3.90
Low Today
$3.77
Open Price
$3.81
Volume
494.44K
52 Week High
$5.19
52 Week Low
$1.82

Collections

GLYC Earnings

-$0.39
-$0.26
-$0.13
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 26, Pre-Market

You May Also Like

ENVIU
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure